FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1604082007> ?p ?o ?g. }

• W1604082007 endingPage "742" @default.
• W1604082007 startingPage "732" @default.
• W1604082007 abstract "BACKGROUND Carboxypeptidase-D (CPD) cleaves C-terminal arginine for nitric oxide (NO) production. CPD and NO levels are upregulated by testosterone (T) and prolactin (PRL) to promote survival of prostate cancer (pCa) cells. This study evaluated CPD immunostaining and T/PRL regulation of CPD and NO levels in benign and malignant prostate tissues/cells to determine the role of CPD in pCa. METHODS Immunohistochemistry (IHC) and tissue microarrays (TMA) were used to determine CPD immunostaining in prostate specimens. QPCR and immunoblotting were used to quantify CPD mRNA/protein expression in prostate cells. NO production was measured using 4,5-diaminofluorescein diacetate assay. RESULTS CPD staining increased from 8.9 ± 3.8% (Mean ± SEM, n = 15) of benign epithelial cell area to 30.9 ± 2.9% (n = 30) of tumor cell area in one set of TMAs (P = 0.0008) and from 5.9 ± 0.9% (n = 45) of benign epithelial cell area to 18.8 ± 1.9% (n = 55) of tumor area in another (P < 0.0001). IHC of prostate tissues (≥50 mm2) confirmed increased CPD staining, from 13.1 ± 2.9% in benign (n = 16) to 29.5 ± 4.4% in pCa (n = 31, P = 0.0095). T and/or PRL increased CPD expression in several pCa but not benign cell lines. T and PRL acted synergistically to increase NO production, which was abolished only when receptor antagonists flutamide and Δ1–9-G129R-hPRL were used together. CONCLUSIONS CPD immunostaining and T/PRL-stimulated CPD expression were higher in pCa than benign tissues/cells. Elevated CPD increased NO production, which was abolished when both AR and PRLR were inhibited. Our study implicates a critical role for the T/PRL-stimulated CPD-Arg-NO pathway in pCa progression, and suggests that AR+PRLR inhibition is a more effective treatment for pCa. Prostate 74:732–742, 2014. © 2014 Wiley Periodicals, Inc." @default.
• W1604082007 created "2016-06-24" @default.
• W1604082007 creator A5020049498 @default.
• W1604082007 creator A5029784853 @default.
• W1604082007 creator A5041012326 @default.
• W1604082007 creator A5043219978 @default.
• W1604082007 creator A5056487607 @default.
• W1604082007 creator A5078717940 @default.
• W1604082007 date "2014-02-24" @default.
• W1604082007 modified "2023-10-06" @default.
• W1604082007 title "Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting" @default.
• W1604082007 cites W174805935 @default.
• W1604082007 cites W1776913920 @default.
• W1604082007 cites W1821918060 @default.
• W1604082007 cites W1929011282 @default.
• W1604082007 cites W1965283402 @default.
• W1604082007 cites W1976292966 @default.
• W1604082007 cites W1976887945 @default.
• W1604082007 cites W1978944815 @default.
• W1604082007 cites W1978960998 @default.
• W1604082007 cites W1982432279 @default.
• W1604082007 cites W2007951687 @default.
• W1604082007 cites W2008691375 @default.
• W1604082007 cites W2011501880 @default.
• W1604082007 cites W2013122061 @default.
• W1604082007 cites W2015157188 @default.
• W1604082007 cites W2016594281 @default.
• W1604082007 cites W2020242649 @default.
• W1604082007 cites W2020894510 @default.
• W1604082007 cites W2022635468 @default.
• W1604082007 cites W2028606939 @default.
• W1604082007 cites W2037223213 @default.
• W1604082007 cites W2044612493 @default.
• W1604082007 cites W2045902586 @default.
• W1604082007 cites W2047710345 @default.
• W1604082007 cites W2052528687 @default.
• W1604082007 cites W2061911613 @default.
• W1604082007 cites W2080439368 @default.
• W1604082007 cites W2080487345 @default.
• W1604082007 cites W2081365151 @default.
• W1604082007 cites W2081576253 @default.
• W1604082007 cites W2086964180 @default.
• W1604082007 cites W2087727186 @default.
• W1604082007 cites W2088371750 @default.
• W1604082007 cites W2090334533 @default.
• W1604082007 cites W2090499110 @default.
• W1604082007 cites W2091571305 @default.
• W1604082007 cites W2092707882 @default.
• W1604082007 cites W2097382536 @default.
• W1604082007 cites W2099356955 @default.
• W1604082007 cites W2117296712 @default.
• W1604082007 cites W2145372894 @default.
• W1604082007 cites W2152206584 @default.
• W1604082007 cites W2159132187 @default.
• W1604082007 cites W2165108408 @default.
• W1604082007 cites W2165122774 @default.
• W1604082007 cites W2168133067 @default.
• W1604082007 cites W2169489306 @default.
• W1604082007 cites W2171110335 @default.
• W1604082007 cites W2290801244 @default.
• W1604082007 cites W4254037116 @default.
• W1604082007 cites W4255410319 @default.
• W1604082007 cites W4376545141 @default.
• W1604082007 doi "https://doi.org/10.1002/pros.22793" @default.
• W1604082007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24615730" @default.
• W1604082007 hasPublicationYear "2014" @default.
• W1604082007 type Work @default.
• W1604082007 sameAs 1604082007 @default.
• W1604082007 citedByCount "14" @default.
• W1604082007 countsByYear W16040820072014 @default.
• W1604082007 countsByYear W16040820072015 @default.
• W1604082007 countsByYear W16040820072016 @default.
• W1604082007 countsByYear W16040820072017 @default.
• W1604082007 countsByYear W16040820072019 @default.
• W1604082007 countsByYear W16040820072020 @default.
• W1604082007 countsByYear W16040820072022 @default.
• W1604082007 countsByYear W16040820072023 @default.
• W1604082007 crossrefType "journal-article" @default.
• W1604082007 hasAuthorship W1604082007A5020049498 @default.
• W1604082007 hasAuthorship W1604082007A5029784853 @default.
• W1604082007 hasAuthorship W1604082007A5041012326 @default.
• W1604082007 hasAuthorship W1604082007A5043219978 @default.
• W1604082007 hasAuthorship W1604082007A5056487607 @default.
• W1604082007 hasAuthorship W1604082007A5078717940 @default.
• W1604082007 hasConcept C121608353 @default.
• W1604082007 hasConcept C126322002 @default.
• W1604082007 hasConcept C134018914 @default.
• W1604082007 hasConcept C142724271 @default.
• W1604082007 hasConcept C170493617 @default.
• W1604082007 hasConcept C193270364 @default.
• W1604082007 hasConcept C204232928 @default.
• W1604082007 hasConcept C2776235491 @default.
• W1604082007 hasConcept C2777152744 @default.
• W1604082007 hasConcept C2779064019 @default.
• W1604082007 hasConcept C2780192828 @default.
• W1604082007 hasConcept C2781031661 @default.
• W1604082007 hasConcept C4224716 @default.
• W1604082007 hasConcept C61367390 @default.

• next